Use of antibiotics in the treatment of inflammatory bowel disease (Q36521201)

14 August 2017

1 reference

title

Use of antibiotics in the treatment of inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

14 August 2017

main subject

0 references

author name string

Molly Perencevich

series ordinal

1 reference

14 August 2017

Robert Burakoff

series ordinal

1 reference

14 August 2017

publication date

1 July 2006

1 reference

Inflammatory Bowel Diseases

14 August 2017

published in

1 reference

14 August 2017

1 reference

14 August 2017

1 reference

14 August 2017

page(s)

651-664

1 reference

Inflammatory Bowel Disease

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Microbial factors in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Host-flora interactions in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Mucosal flora in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Dysbiosis in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Membrane recruitment of NOD2 in intestinal epithelial cells is essential for nuclear factor-{kappa}B activation in muramyl dipeptide recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

State of the art: IBD therapy and clinical trials in IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Treatment of inflammatory bowel disease with antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Antibiotics for inflammatory bowel disease: do they work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Review article: antibiotics and probiotics in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Antibacterial and antimycobacterial treatment for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Treatment of inflammatory bowel disease: safety and tolerability issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Fluoroquinolone-associated tendinopathy: a critical review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Fluoroquinolones cause changes in extracellular matrix, signalling proteins, metalloproteinases and caspase-3 in cultured human tendon cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Antibiotic use and the development of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Antibiotic use and the risk of flare of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Preliminary study of ciprofloxacin in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Antibiotics should be used as first-line therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

The role of antibiotics in the management of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Antibiotics as a first-line therapy for Crohn's disease: is there any consensus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Postoperative Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Johne's and Crohn's. Chronic inflammatory bowel diseases of infectious aetiology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

PCR detection of Mycobacterium paratuberculosis in Crohn's disease granulomas isolated by laser capture microdissection

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Detection and verification of Mycobacterium avium subsp. paratuberculosis in fresh ileocolonic mucosal biopsy specimens from individuals with and without Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Antibacterial therapy for Crohn's disease: a review emphasizing therapy directed against mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Open label trial of oral clarithromycin in active Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Treatment of severe Crohn's disease using antimycobacterial triple therapy--approaching a cure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Medical management of severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Clinical approach to diseases of ileal pouch-anal anastomosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Clinical management of pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Diagnosis and treatment of pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Budesonide enema in pouchitis--a double-blind, double-dummy, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Management of inflammatory bowel disease: does rifaximin offer any promise?

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

An open-label evaluation of rifaximin in the treatment of active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Corticosteroid-sparing effect of rifaximin, a nonabsorbable oral antibiotic, in active ulcerative colitis: Preliminary clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Probiotics and the management of inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.MIB.0000225330.38119.C7

10.1097/01.MIB.0000225330.38119.C7

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference